Rosetta Genomics Reports 2015 Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Six dead in 'stampede-like' incident at India temple, ANI says
Aegis Capital Still Positive on Rosetta Genomics (ROSG) Following Q4 Results; Nudges Ests Higher
March 24, 2016 11:41 AM EDTAegis Capital affirms Rosetta Genomics (NASDAQ: ROSG) with a Buy rating and $3.50 price target after ROSG reported Q4/FY15 results earlier Thursday.
Analyst Robert LeBoyer commented, We believe this quarterly report confirms our belief that the company has high-value cancer diagnostic... More
Rosetta Genomics (ROSG) Files $75M Mixed Shelf
March 23, 2016 4:48 PM EDTRosetta Genomics (NASDAQ: ROSG) filed a registration with the U.S. SEC to sell, from time to time, up to $75 million worth of mixed securities.
... MoreRosetta Genomics (ROSG) Reports Q4 Loss Per Share of $0.14
March 23, 2016 4:16 PM EDTRosetta Genomics (NASDAQ: ROSG) reported Q4 EPS of ($0.14). Revenue for the quarter came in at $3.6 million, versus $698 thousand reported last year.
For earnings history and earnings-related data on Rosetta Genomics (ROSG) click here.
... More